Investing.comDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 04:07:42·⟳ 抓取 04:08:26 +44s·⚡ 决策 10-16 04:14:31 +6m05s·11.7 天前
PTAB再次维持华盛顿大学/TwinStrand的'127专利全部30项权利有效，驳回Guardant Health无效挑战
PTAB本次决定关闭的是Guardant的一条专利无效抗辩路径，但2.452亿美元赔偿加6%持续提成费的核心经济责任已在2026年8月24日终审判决中确定并被广泛报道，Guardant同日宣布上诉，市场已消化；该赔偿仅占GH约222.6亿美元市值的约1.1%，盘后股价持平、成交量低，无新增重定价，不构成可交易的强空催化。
📄 原文Investing.com↗ 原文
PTAB upholds University of Washington patent against Guardant challenge
Nasdaq ends higher in big rebound as bond rally offsets tech softness, hot PPI SEATTLE - The U.S. Patent and Trademark…
不做 Guardant Health（GH.US）
方向偏空但无新增可交易edge：2.452亿美元赔偿+6%提成费已于2026年8月24日终审确定并广泛报道（约占222.6亿美元市值1.1%），本次PTAB仅程序性维持专利有效、Guardant已在上诉，现行Reveal/Shield被排除且已设计规避；盘后股价持平、量极低，视为已price-in，强空催化不成立，不开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
PTAB再次维持涉案专利有效，对Guardant Health方向偏空，但实质赔偿与提成费已于8月终审确定且公司在上诉，本次属程序性确认、增量有限，盘后无反应，判定已price-in，不做。
消息传播链
- 报道PTAB在发回重审后再次维持'127专利全部30项权利要求；消息源自TwinStrand新闻稿，Investing.com为二手转述市场反应:GH盘后约165.88美元，持平，盘后成交约1.34万股，无显著反应
关键理由
- 核心2.452亿美元赔偿及6%提成费已于2026年8月终审入账并被Reuters等广泛报道，本次PTAB决定未新增金额或新禁令
- 赔偿约占GH市值1.1%，且Guardant Reveal、Shield现行产品被排除在终审命令之外，公司称已验证Guardant360设计规避，实质经营冲击有限
主要风险
- 若Guardant对地区法院判决上诉失败或'631专利再审再失利，可能确认提成费长期化，但属渐进信息而非当日催化
- 新闻稿来自TwinStrand单方声明（Investing.com转述），具体PTAB文书措辞尚需核对
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
公司称现行主力产品被排除在命令外并已完成设计规避，且赔偿仅约市值1.1%，削弱做空重大性
检索:Guardant Health appeal Reveal Shield excluded design-around Guardant360 patent 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
核心利空在8月终审时已披露，本次仅PTAB程序确认，盘后零反应、无放量，不支持新增做空edge
检索:Guardant Health stock reaction patent verdict August 24 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件增量小，支持AVOID而非据名义利空开空
方向:无可供量化的同类专利IPR重审维持先例面板；本案核心经济冲击锚点在2026年8月终审判决而非本次PTAB决定
涨幅量级:不足：未检索到与本次'发回重审后PTAB再次维持专利'高度同构且有干净首发锚的上市公司日线样本，不用以校准幅度
形态:盘后价格零反应与8月赔偿已入账的事实，更支持'程序性确认无增量'而非新做空窗口
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`gh nasdaq ptab final written decision patent challenge rejected | guardant health duplex sequencing patent ruling damages 245 million royalty | guardant health ptab university of w`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 1,010 ms
{ - web_search 成功 doubao_search · 1,180 ms
豆包搜索结果（原始查询:Guardant Health PTAB ruling University of Washington TwinStrand patent 10,760,127 October 2026；API SearchType:web） - web_search 成功 doubao_search · 1,507 ms
豆包搜索结果（原始查询:Guardant Health TwinStrand patent verdict $245 million royalty 6% Delaware final judgment August 2026；API SearchType:web） - validate_order 成功 stock_tools HTTP · 7 ms
{
原文全文
展开原文 · 2,013 字
Nasdaq ends higher in big rebound as bond rally offsets tech softness, hot PPI
SEATTLE - The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board ruled on Tuesday in favor of the University of Washington and TwinStrand Biosciences, rejecting Guardant Health Inc.’s (NASDAQ:GH) challenge to all 30 claims of U.S. Patent No. 10,760,127, according to a press release statement.
The Final Written Decision follows a remand from the U.S. Court of Appeals for the Federal Circuit. The patent, owned by the University of Washington and exclusively licensed to TwinStrand Biosciences, covers technology underlying Duplex Sequencing.
The PTAB previously ruled in favor of the University of Washington in October 2023 during an inter partes review of the patent. Guardant Health appealed that decision, and in January 2026, the Federal Circuit directed the PTAB to reconsider the challenge under a different legal framework. Applying the new analysis specified by the appeals court, the PTAB again determined that Guardant Health failed to establish the unpatentability of the challenged claims.
The ’127 patent is one of two patents involved in patent infringement litigation TwinStrand brought against Guardant Health in the U.S. District Court for the District of Delaware. Final judgment in that case was entered in August in favor of TwinStrand and the University of Washington, preserving a November 2023 jury verdict that found Guardant Health willfully infringed the ’127 patent and U.S. Patent No. 10,287,631.
The jury awarded more than $245.2 million in damages, accrued royalties and interest for infringement through May. Guardant Health was also ordered to pay an ongoing royalty of 6% on covered products and services through March 2033, when the patents expire. A separate re-examination proceeding involving the ’631 patent remains ongoing before the U.S. Patent and Trademark Office.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SEATTLE - The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board ruled on Tuesday in favor of the University of Washington and TwinStrand Biosciences, rejecting Guardant Health Inc.’s (NASDAQ:GH) challenge to all 30 claims of U.S. Patent No. 10,760,127, according to a press release statement.
The Final Written Decision follows a remand from the U.S. Court of Appeals for the Federal Circuit. The patent, owned by the University of Washington and exclusively licensed to TwinStrand Biosciences, covers technology underlying Duplex Sequencing.
The PTAB previously ruled in favor of the University of Washington in October 2023 during an inter partes review of the patent. Guardant Health appealed that decision, and in January 2026, the Federal Circuit directed the PTAB to reconsider the challenge under a different legal framework. Applying the new analysis specified by the appeals court, the PTAB again determined that Guardant Health failed to establish the unpatentability of the challenged claims.
The ’127 patent is one of two patents involved in patent infringement litigation TwinStrand brought against Guardant Health in the U.S. District Court for the District of Delaware. Final judgment in that case was entered in August in favor of TwinStrand and the University of Washington, preserving a November 2023 jury verdict that found Guardant Health willfully infringed the ’127 patent and U.S. Patent No. 10,287,631.
The jury awarded more than $245.2 million in damages, accrued royalties and interest for infringement through May. Guardant Health was also ordered to pay an ongoing royalty of 6% on covered products and services through March 2033, when the patents expire. A separate re-examination proceeding involving the ’631 patent remains ongoing before the U.S. Patent and Trademark Office.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
7509177a67· 2026-10-16 04:14 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前